In conclusion, our results suggest that expression of different combinations of receptor can change the final outcome of the disease, and we suggest that the expression of HER3 and HER4 should be taken into account for future evaluation of the consequences of HER1 and HER2 expression in bladder cancer. This evidence concerns the gene ERBB4 and urinary bladder cancer.